Drug Development With AI: From Discovery to Regulatory Submission

A practical walkthrough of how artificial intelligence and machine learning are being deployed across the modern drug development lifecycle — the transition from computational discovery to translational, clinical, and regulatory workstreams that actually ship medicines.

Why "drug development" is the harder half

AI in drug discovery — generative chemistry, protein structure prediction, target identification — dominates the headlines. But between a promising molecule and an approved therapy sits drug development: pre-clinical safety, CMC (chemistry, manufacturing, and controls), clinical trials, biostatistics, and regulatory submission. This is where the great majority of programs still fail — industry analyses put overall transition-to-approval success in the single digits to low teens of percent — where timelines stretch to a decade, and where AI is now producing its most consequential — and most scrutinized — wins.

This guide is written for biotech and biopharma professionals who already understand the science and want a grounded view of where AI is genuinely moving the needle across the development pipeline, and where it is still hype.

The development lifecycle at a glance

1. Target identification & validation — often grouped with discovery, but the handoff to development starts here.
2. Lead optimization — ADMET, potency, and developability trade-offs.
3. Pre-clinical development — in vitro / in vivo pharmacology, toxicology, PK/PD.
4. IND-enabling studies — GLP toxicology, CMC package.
5. Clinical trials — Phase 1 (safety), Phase 2 (efficacy signal), Phase 3 (pivotal).
6. Regulatory submission — NDA / BLA / MAA and post-approval commitments.
7. Post-market surveillance — pharmacovigilance and real-world evidence.

1. Pre-clinical: AI for ADMET, tox, and PK/PD

Pre-clinical is where machine learning has been embedded longest. Modern practice looks like:

• ADMET prediction models — solubility, permeability, hERG liability, CYP450 interaction, and hepatotoxicity are routinely predicted from structure using graph neural networks or transformer-based property predictors.
• Physiologically-based PK (PBPK) with ML priors — hybrid models that use ML to estimate parameters (clearance, tissue partition) which then feed a mechanistic PBPK simulator.
• In silico toxicology — read-across and QSAR pipelines that support weight-of-evidence arguments for reducing animal studies, aligned with the FDA Modernization Act 2.0. [6]
• Digital pathology — CNN-based scoring of tox study slides, applied consistently and complementing manual reads; pathologists remain the reviewers of record.

Practical caveat: for the pivotal safety studies that support an IND, regulators still expect GLP-compliant work; these tools mainly shape which molecules earn the tox budget in the first place.

2. CMC and manufacturing

CMC is the quietly transformed corner of AI in drug development: design-of-experiments accelerators in process development, soft sensors on Raman / NIR spectra predicting critical quality attributes in real time, anomaly detection on bioreactor time-series, and yield forecasting for cell and gene therapy programs where yields are inherently variable.

Where the money actually is, and why small models tend to beat large ones here, is covered in AI in Process Development and CMC.

3. Clinical trial design and operations

This is where the largest financial stakes sit: a Phase 3 trial is a nine-figure undertaking, so even single-digit improvements in enrollment or retention compound into meaningful savings. The shape of it:

• Protocol optimization — LLMs comparing draft protocols against historical corpora to flag inclusion/exclusion criteria likely to bottleneck enrollment.
• Patient identification — NLP over EHRs and pathology reports to surface eligible patients, especially in oncology and rare disease.
• Digital endpoints — wearable- and phone-derived measures (gait, cough, cognitive tests) validated as fit-for-purpose endpoints in neurology and cardiology programs.
• Synthetic control arms & external comparators — propensity-score matched cohorts from real-world data. FDA has issued guidance on externally controlled trials and has accepted external controls in some rare-disease and pediatric settings; acceptance remains indication-specific and is never assumed.
• Adaptive designs — Bayesian and reinforcement-learning-informed trial designs that update dose or allocation as data accrues.

Two pieces go deeper: AI for Trial Feasibility and Site Selection on ranking investigator sites and forecasting enrollment, and Working With Clinical Trial Data Using AI Models on the data-quality and coding work once a trial is running.

4. Biostatistics, safety, and pharmacovigilance

• Automated case processing — NLP triage of individual case safety reports (ICSRs), narrative generation, and MedDRA coding, reviewed by a qualified person.
• Signal detection — disproportionality analysis augmented with ML on FAERS, VigiBase, and internal safety databases.
• Missing data and imputation — modern ML imputation methods (with appropriate sensitivity analyses) inside the statistical analysis plan.

5. Regulatory submission and the FDA framework

The regulatory picture in 2026 is far clearer than it was three years ago. The anchors every sponsor should know:

• FDA's 2025 draft guidance on the use of AI to support regulatory decision-making for drugs and biologics — introducing the credibility assessment framework and the concept of context of use. [1]
• ICH E6(R3) GCP — modernized to accommodate decentralized trials and computational tools. [2]
• ICH M15 — the emerging model informed drug development (MIDD) harmonized guideline. [3]
• 21 CFR Part 11 — still the backbone for electronic records. It applies directly to closed systems and signatures; whether a given AI tool falls in scope depends on the system, the records it creates, and its intended use, so sponsors typically scope validation to tools whose output feeds a submission. [4]
• Good Machine Learning Practice (GMLP) — jointly published by FDA, Health Canada, and MHRA, ten guiding principles written for medical devices that sponsors increasingly borrow as the vocabulary for drug-side AI quality conversations too. [5]

Drafting submission text with LLMs while keeping that audit trail intact is its own discipline, covered in AI in Regulatory Writing.

The through-line: regulators do not evaluate a model in the abstract. They evaluate a specific model used for a specific decision, with credibility evidence proportional to the risk of getting that decision wrong. Frame every AI component of a submission this way.

Practical stack: what teams are actually using

Rather than list vendors, here is the shape of a modern development stack that has AI woven through it:

• Data layer — a validated data lake spanning ELN, LIMS, EDC, safety, and CMC systems, with lineage tracked at column level.
• Modeling layer — a mix of vendor tools (ADMET, imaging, NLP) and internal models governed by an MLOps stack with model cards and versioned artifacts.
• Decision layer — dashboards and copilots that expose model outputs to scientists, clinicians, and reviewers, always with the confidence and provenance visible.
• Governance layer — an AI governance council, a model inventory, and SOPs mapping every model to its context of use and validation status.

How it works in practice

Development teams rarely deploy one large model. They run several narrow ones, each with its own inputs and validation, and the pattern below is what a typical one looks like end to end.

• What data goes in. Compound structures and assay histories for ADMET work; process parameters, sensor traces and batch records for CMC; historical trial operational data and site performance for clinical planning; and case narratives and coded terms for safety.
• What the model predicts or ranks. A single, specific quantity — predicted clearance or hERG liability, predicted critical quality attribute, predicted enrolment rate at a site, predicted case seriousness — not a broad recommendation.
• Technique or model family. Gradient-boosted trees and random forests on tabular descriptors dominate, with graph neural networks for molecules, Gaussian processes and Bayesian optimization for experimental design, and language models confined to text-heavy tasks such as narrative and document work.
• How it is trained or validated. Split by time, scaffold, site or batch depending on the domain, so the test set represents the future rather than a reshuffle of the past. Regulated uses add an intended-use statement and validation evidence proportional to risk.
• What the team does with the output. The prediction changes an allocation decision: which compound gets synthesized, which conditions get run, which sites get activated, which cases get expedited review. A human still owns the decision and the record.
• A representative example. Input: a candidate structure with its physicochemical descriptors. Output: predicted microsomal clearance in the high bin, with the nearest training analogues shown. The chemistry team deprioritizes the series rather than declaring the compound dead — and the actual assay, when run, is what enters the record.

Common failure modes

• Buying a "platform" before defining a decision. Start with the specific development decision the model informs.
• Under-scoping validation. Regulators expect validation on data representative of the deployment population, not the training set.
• Treating LLMs as sources of truth in regulated workflows. They are drafting aids; the human owns the record.
• Ignoring MLOps. A model without monitoring will drift; a drifting model in CMC or safety is a compliance problem.

Sources

1. U.S. Food and Drug Administration — Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products (draft guidance)
2. ICH — ICH E6(R3) Guideline for Good Clinical Practice
3. ICH — Multidisciplinary Guidelines: M15 Model-Informed Drug Development
4. U.S. Electronic Code of Federal Regulations — 21 CFR Part 11: Electronic Records; Electronic Signatures
5. FDA, Health Canada and MHRA — Good Machine Learning Practice for Medical Device Development: Guiding Principles
6. U.S. Congress — Consolidated Appropriations Act, 2023, Sec. 3209 (FDA Modernization Act 2.0)